The U.S. Food and Drug Administration has accepted Novo Nordisk's marketing application for an oral version of its ...

Wegovy and Ozempic are both semaglutide weight loss medications, but they’re prescribed differently based on who qualifies.

As summer approaches, millions of Americans are turning to weight-loss injections in hopes of shedding pounds—fast. Roughly ...

The FDA accepted Novo Nordisk's NDA for an oral formulation of Wegovy. The agency is expected to release its verdict on the ...

Hims & Hers stock has surged due to impressive quarterly results, rapid weight-loss product expansion, and a strategic Novo ...

A decision is expected in the fourth quarter of 2025.

A recent clinical trial reveals that Wegovy, a popular weight-loss drug containing semaglutide, shows promising results in treating liver diseases like MASH. The study, published in the New ...

This time next year, you may be swapping your GLP-1 injections for easier and as-effective oral weight-loss medication. It's ...

As weight-loss injectables like Ozempic skyrocket in popularity, a new offshoot trend is starting to take hold: microdosing. But experts have concerns.

Weight loss medications and bariatric surgery used to be considered last-resort options, but now, they’re everywhere. More ...

Novo Nordisk on Wednesday reported a better-than-expected rise in net profit but lowered its full-year sales growth forecast.

Shares in Novo Nordisk were still up after Q1 2025 witnessed a total revenue jump by 18%, compared to Q1 2024.